# Nintedanib(BIBF1120) in Thyroid Cancer

> **NCT01788982** · PHASE2 · COMPLETED · sponsor: **European Organisation for Research and Treatment of Cancer - EORTC** · enrollment: 100 (actual)

## Conditions studied

- Medullary Thyroid Cancer (MTC)
- Differentiated Thyroid Cancer (DTC)

## Interventions

- **DRUG:** Nintedanib
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT01788982
- **Lead sponsor:** European Organisation for Research and Treatment of Cancer - EORTC
- **Sponsor class:** NETWORK
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2014-05
- **Primary completion:** 2019-08-28
- **Final completion:** 2019-08-28
- **Target enrollment:** 100 (ACTUAL)
- **Last updated:** 2020-07-31


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01788982

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01788982, "Nintedanib(BIBF1120) in Thyroid Cancer". Retrieved via AI Analytics 2026-06-08 from https://api.ai-analytics.org/clinical/NCT01788982. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*